Evaluation of the Hematologic Safety of Same Day Vs Standard Administration of Pegfilgrastim in Gynecology Oncology Patients

abstract

CONCLUSIONS:
The incidence of hematologic toxicities and dose modification in patients receiving same-day pegfilgrastim were not as low as in those undergoing standard administration. However, treatment delays were found to be no more frequent in those receiving same-day pegfilgrastim versus standard administration. Same-day administration of pegfilgrastim is a reasonable option.